부산대학교 도서관

The aim of this study was to evaluate the baseline demographics and real-life efficacy of direct acting antivirals (DAAs) in HIV–HCV-positive patients as compared to patients with HCV monoinfection. The analysis included 5690 subjects who were treated with DAAs: 5533 were HCV-positive and 157 were HIV–HCV-positive. Patients with HCV-monoinfection were older (p <.0001) and in HIV–HCV group there were more men (p <.0001). Prevalence of genotype 1a (p =.002), as well as of genotypes 3 and 4 (p <.0001) was higher in HIV–HCV-coinfected patients. Genotype 1b was more frequent (p <.0001) in the HCV-mono-infection group. Patients with HCV-monoinfection had a higher proportion of fibrosis F4 (p =.0004) and lower proportion of fibrosis F2 (p <.0001). HIV–HCV-coinfected individuals were more often treatment-naïve (p <.0001). Rates of sustained viral response after 12 weeks did not differ significantly between both groups (95.9% versus 97.3% in coinfection and monoinfection group, respectively; p >.05). They were, however, influenced by HCV genotype (p <.0001), stage of hepatic fibrosis (p <.0001), male sex (p <.0001), BMI (p =.0001) and treatment regimen modifications (p <.0001). Although factors associated with worse response to therapy (male sex, genotype 3) occurred more often in the HIV coinfection group, real-life results of DAAs did not differ significantly between both populations. [ABSTRACT FROM AUTHOR]